HCHB and element5 form strategic alliance to accelerate the agentic AI movement in post-acute care
Element5’s Agentic AI platform will be integrated with the HCHB EHR
Element5’s Agentic AI platform will be integrated with the HCHB EHR
CRISPR-based detection enables highly specific molecular recognition
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Subscribe To Our Newsletter & Stay Updated